7-nitro-1H-indene | 85397-26-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: 7-nitro-1H-indene
• 英文别名: 7-Nitroinden
• CAS: 85397-26-8
• 化学式: C₉H₇NO₂
• 分子量: 161.16
• InChiKey: XIABDXIZFQYNDM-UHFFFAOYSA-N

物化性质

• 沸点：
  284.3±29.0 °C(Predicted)
• 密度：
  1.303±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-nitro-1H-indene 在 rhodium(III) chloride 作用下， 以 乙醇 为溶剂， 以43%的产率得到4-nitro-1H-indene
  参考文献：
  名称：

  Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel

  摘要：

  A collection of aryl sulfonamido indanes based on the lead compound I was synthesized and evaluated for Kv1.5 inhibitory activity. Kv1.5 inhibitors have the potential to be atrium-selective agents for treatment of atrial fibrillation. (1R,2R)-1 has an IC50 of 0.033 mu M against Kv1.5 and is selective against other cardiac ion channels, including hERG. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.052
• 作为产物：
  描述：

  茚满 在 sodium tetrahydroborate 、 硫酸 、 硝酸 、 对甲苯磺酸 作用下， 以 甲醇 、 甲苯 为溶剂， 生成 7-nitro-1H-indene
  参考文献：
  名称：

  Aryl sulfonamido indane inhibitors of the Kv1.5 ion channel

  摘要：

  A collection of aryl sulfonamido indanes based on the lead compound I was synthesized and evaluated for Kv1.5 inhibitory activity. Kv1.5 inhibitors have the potential to be atrium-selective agents for treatment of atrial fibrillation. (1R,2R)-1 has an IC50 of 0.033 mu M against Kv1.5 and is selective against other cardiac ion channels, including hERG. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.02.052

文献信息

• [EN] SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE CARBOXAMIDE AROMATIQUE ET D'URÉE SUBSTITUÉS EN TANT QUE LIGANDS DU RÉCEPTEUR VANILLOÏDE
  申请人：GRUENENTHAL GMBH

  公开号：WO2010127855A1

  公开（公告）日：2010-11-11

  The invention relates to substituted aromatic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions (formula (I)).

  这项发明涉及取代芳香族羧酰胺和脲衍生物，以及其制备方法，含有这些化合物的药物组合物，以及利用这些化合物制备药物组合物的用途（式（I））。
• [EN] TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES<br/>[FR] DERIVES DE TETRAHYDRO-NAPHTHALENE ET D'UREE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2005040100A1

  公开（公告）日：2005-05-06

  This invention relates to tetrahydro-naphthalene and urea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-naphthalene and urea derivatives of the present invention have vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor oeractivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD). BHC 03 2 001-Foreign-Countries - 66 - BHC 03 2 001-Foreign-Countries - 65 -

  这项发明涉及四氢萘和脲衍生物及其盐，这些物质可作为药物制剂的活性成分。本发明的四氢萘和脲衍生物具有辣椒素受体（VR1）拮抗活性，可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗与VR1活性相关的泌尿系统疾病或紊乱，如膀胱过度活动（过度活跃膀胱）、尿失禁、神经源性膀胱过度活动（膀胱过度反射）、特发性膀胱过度活动（膀胱不稳定）、良性前列腺增生、下尿路症状；慢性疼痛、神经病性疼痛、术后疼痛、类风湿性关节炎疼痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风，以及哮喘和慢性阻塞性肺病（COPD）等炎症性疾病。BHC 03 2 001-外国国家 - 66 - BHC 03 2 001-外国国家 - 65 -
• Vanilloid receptor ligands and their use in treatments
  申请人：Doherty M. Elizabeth

  公开号：US20060241296A1

  公开（公告）日：2006-10-26

  Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  具有一般结构和成分的化合物及其含量，用于治疗急性、炎症性和神经性疼痛、牙痛、普通头痛、偏头痛、群头痛、混合血管和非血管综合症、紧张性头痛、一般炎症、关节炎、风湿性疾病、骨关节炎、炎性肠道疾病、炎性眼部疾病、炎性或不稳定膀胱疾病、银屑病、带有炎症成分的皮肤疾病、慢性炎症疾病、炎症性疼痛和相关的过敏症和痛觉过敏、神经性疼痛和相关的过敏症和痛觉过敏、糖尿病性神经病疼痛、烧灼性疼痛、交感神经维持性疼痛、去神经综合症、哮喘、上皮组织损伤或功能障碍，单纯疱疹、呼吸、泌尿、消化或血管区域内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒症、白癜风、一般胃肠道疾病、胃溃疡、十二指肠溃疡、腹泻、由坏死性剂引起的胃病变、头发生长、血管运动或过敏性鼻炎、支气管疾病或膀胱疾病。
• [EN] TETRAHYDRO-NAPHTHALENE AND UREA DERIVATIVES<br/>[FR] TETRAHYDRO-NAPHTALENE ET DERIVES D'UREE
  申请人：BAYER HEALTHCARE AG

  公开号：WO2005040119A1

  公开（公告）日：2005-05-06

  This invention relates to a hydroxy-tetrahydro-naphthalene or an urea derivative formula (I) and salts thereof which are useful as active ingredients of pharmaceutical preparations, wherein A represents formula (II) or (III) wherein # represents the connection position to the molecule and Q1a, Q2a, Q3a and Q4a are defined, and E represents formula (IV) or (V) wherein # represents the connection position to the molecule and Q1b, Q2b, Q3b, Q4b, Q5b, R1b, na, ma, Xa and Ra are defined.

  这项发明涉及一种羟基四氢萘或脲衍生物公式(I)及其盐，它们作为药物制剂的活性成分，其中A代表公式(II)或(III)，其中#代表分子的连接位置，Q1a、Q2a、Q3a和Q4a被定义，E代表公式(IV)或(V)，其中#代表分子的连接位置，Q1b、Q2b、Q3b、Q4b、Q5b、R1b、na、ma、Xa和Ra被定义。
• 4-Heterocyclic-substituted-2-indanyl alcohols and insecticidal ester
  申请人：FMC Corporation

  公开号：US04368205A1

  公开（公告）日：1983-01-11

  Disclosed are novel compounds of the formula ##STR1## wherein R.sup.1 is a heterocyclic radical selected from furanyl, thienyl, pyridyl, pyrimidyl, oxazolyl, pyrrolyl, isoxazolyl, thiazolyl, and isothiazolyl, and R.sup.2 is hydrogen, a tetramethylcylopropanecarbonyl group, a 1-(substituted-phenyl)-2-methylpropyl-1-carbonyl group, a 1-(4-ethoxyphenyl)-2-dichlorocyclopropanecarbonyl group, or a substituted-vinyl-cyclopropanecarbonyl group. The compounds wherein R.sup.2 is other than hydrogen are insecticides.

  揭示了以下式的新化合物 ##STR1## 其中 R.sup.1 是从呋喃基、噻吩基、吡啶基、嘧啶基、噁唑基、吡咯基、异噁唑基、噻唑基和异噻唑基中选择的杂环基团，R.sup.2 是氢、四甲基环丙酰基、1-(取代苯基)-2-甲基丙基-1-羰基基团、1-(4-乙氧基苯基)-2-二氯环丙酰基团或取代乙烯基环丙酰基团。其中 R.sup.2 不是氢的化合物是杀虫剂。